AzTrials
AzTrials

Borderline Personality DisorderNCT04157907

Reflective Functioning and Psychotherapy Processes in MBT

An observational study of Borderline Personality Disorder, run by Oslo University Hospital at 1 site in Norway.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Borderline personality disorder (BPD) is a pervasive mental disorder characterized by emotional instability, self-destructive behavior, identity problems and unstable relationships. Read more about this study

Who is it for?
Ages 18 to 40 years
Conditions the study is for
Borderline Personality Disorder
What is being tested?
Mentalization based therapy
How many people
60 participants
Where
1 siteNorway
Study dates
1 Nov 2019to 28 Feb 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • All sexes
  • Adult

Study population: Patients with borderline personality disorder or significant borderline traits, who are treated in the MBT program at the Personality Outpatient Unit, Oslo University Hospital (OUH).

Who may be able to join

  • Borderline personality disorder or significant borderline traits

Who cannot join

  • patients with psychotic disorders as their main problem
  • Asperger's syndrome/autism spectrum disorders
  • low IQ
  • unregulated bipolar I disorders as their main problem

Trial locations and contacts

1 site in 1 country.

Theresa Wilberg, MD PhD contact

+47 22923433

uxthwi@ous-hf.no

Elfrida Hartveit Kvarstein, MD PhD contact

+47 23016940

e.h.kvarstein@medisin.uio.no

Norway1 site, 1 recruiting
  • Personality Outpatient Unit, Section of Personality Psychiatry, Clinic for Mental Health and Addiction, Oslo University Hospital

    Oslo, 4959 Nydalen

    Theresa Wilberg, MD PhD, +47 22923433, uxthwi@ous-hf.no

    Elfrida Hartveit Kvarstein, MD PhD, +47 23016940, e.h.kvarstein@medisin.uio.no

    Recruiting

Other trials in Norway

About this study

Official title: Reflective Functioning and Psychotherapy Processes in Mentalization Based Therapy

Borderline personality disorder (BPD) is a pervasive mental disorder characterized by emotional instability, self-destructive behavior, identity problems and unstable relationships. Persons with this disorder usually experience significant distress in terms of depression, anxieties, suicidal behavior, and difficulties in close relationships as well as with work- and social functioning. Recent research has found the prognosis of BPD to be better than previously assumed, and many patients improve from treatment.

Mentalization based therapy (MBT) is a specialized evidenced based therapy for patients with BPD. Like for other specialized treatments for this disorder, the outcome of therapy is typically variable, some patients respond well to treatment, whereas others respond less. It is therefore important to understand how treatment works in order to improve therapies and tailor treatment to individual patients.

Read more

Mentalizing is the ability to understand ourselves and others in terms of mental states, like intentions, feelings, desires, attitudes, and so on, or briefly; the ability to mind own and other's minds. Impaired mentalizing capacity is an assumed core aspect of BPD, underlying many of the symptoms of this disorder. MBT focuses on the patients mentalizing difficulties and is typically offered as a long-term combined treatment program comprising individual and group therapy, as well as psychoeducation. Several studies have documented positive effects of MBT in terms of reduced suicidal behavior, symptoms, interpersonal problems, medication, and health service use. It is assumed that such clinical improvement is made possible by helping the patients to develop their mentalizing abilities.

Yet, no study has investigated whether patients' mentalizing capacity changes during MBT, or to what degree outcome of MBT is mediated by improved mentalizing. Mentalizing is, however, a complex phenomenon and difficult to measure. Research in this area has been hampered by a lack of suitable methods. Mentalizing is usually operationalized as Reflective Functioning (RF) assessed by the RF Scale. The gold standard is to apply the RF Scale on the Adult Attachment Interview. However, this is a time consuming and costly method, and there is a need for testing other methods as well.

The overall aim of the project is to study treatment processes in MBT for patients with BPD. It focuses on patients' mentalizing difficulties before, during and at the end of therapy. Mentalizing is assessed using different methods. Our main research questions are:

  1. To what degree does patients' level of RF change during MBT?
  2. Is there a relationship between RF and outcome of MBT?
  3. What is the relationship between RF and therapy processes in MBT?
  4. Is it possible to identify in-session processes that promote mentalizing?
  5. What is the clinical utility of various methods of RF assessment?
Read the detailed description

BACKGROUND Borderline personality disorder (BPD) BPD is a pervasive mental disorder characterized by emotional instability, self-destructive behavior, identity problems and unstable interpersonal relationships. The disorder is associated with high levels of symptom distress, suicidal behavior, psychosocial impairment, and high rates of comorbid mental disorders such as mood, anxiety, and substance use disorders, as well as significant health service utilization and costs. Recent research has found the prognosis of BPD to be better than previously assumed. Yet, despite high rates of diagnostic remission many patients continue to have poor vocational and social functioning.

Several specialized and evidence based psychotherapies targeting characteristic BPD symptoms have been developed during the past decades, like Dialectical behavioral therapy, Transference focused therapy, Schema focused therapy and Mentalization based therapy. Across specific treatment approaches the outcome of therapy is typically variable, some patients respond well to treatment, whereas others respond less or even deteriorate. It is therefore important to understand how treatment works in order to improve therapies and tailor treatment to individual patients.

Mentalization based therapy (MBT) MBT is a manualized psychodynamic psychotherapy which focuses specifically on the patients' mentalizing difficulties. Mentalization is defined as the capacity to perceive human behavior as expressions of mental states, like thoughts, affects, dreams and intentions, and is usually operationalized as Reflective Functioning (RF) assessed by the RF Scale. Impaired mentalizing capacity is an assumed core aspect of BPD underlying characteristic features such as poor affect regulation, impulse control problems, and incoherent internal representations of self and others leading to unstable relationships and self- esteem. MBT is prototypically a combined treatment program comprising individual and group therapy, as well as psychoeducation. Several studies, including RCTs have documented positive effects of MBT in terms of reduced suicidal behavior, symptoms, interpersonal problems, medication, and health service use. There are also indications that MBT may be particularly helpful for more severely disturbed patients with extensive comorbidity.

Yet, no study has investigated whether patients' mentalizing capacity changes during MBT, or to what degree outcome of MBT is mediated by improved RF. One study found that outcome of two different treatment approaches (not MBT) differentially depended on patients' pretreatment levels of RF, indicating that RF may be a valuable variable for treatment selection and outcome. There are also indications that RF may improve during Transference focused therapy. However, there is a general lack of studies investigating the role of RF in the unfolding of psychotherapy processes and outcome of MBT. Thus, more studies are needed to gain knowledge of mechanisms of change in MBT.

RF and psychotherapy processes Common therapeutic factors are factors that are believed to function across different types of treatment, in contrast to specific factors which are seen as operating as part of specific therapies and interventions. An early good therapeutic alliance between patient and therapist is the most widely recognized common factor in individual therapies. The Working Alliance Inventory is an established method for assessment of therapeutic alliance in individual therapy. As to group therapies alliance to therapists and group members, as well as group cohesion are suggested as important common factors, but the evidence is not consistent. Assessment of therapeutic factors in groups is, however more complicated due to the many relationships in therapy groups. The Group Questionnaire is a promising empirically derived instrument intended to comprise important dimensions of a patient's relationship to his/her therapy group.

However, the relationship between common and specific therapeutic factors is debated, e.g., specific interventions and factors may be necessary for common factors to come into play. We don't know if specific factors in MBT stimulate alliance and outcome, or if there are other important processes operating. Research should investigate how patients' pretreatment or in-session RF influence the therapeutic alliance to the individual therapist or group, and to what degree interventions intended to stimulate mentalization have an influence on patients' experience of alliance. These are complex processes and other patient characteristic as well as therapeutic interventions must be taken into account when analyzing such processes.

Assessment of RF The gold standard for assessment of RF is the RF Scale applied on the Adult Attachment Interview (AAI) with patient's narratives of his/her experiences with early attachment figures. Yet, the specific mentalizing difficulties often seen in patients with BPD, is a temporary breakdown of mentalizing, particularly during emotional storms in current close relationships. One concern is therefore that RF based on the AAI may not be able to capture such mentalizing collapses. Concordantly, there is incipient evidence that RF based on the AAI may be rather trait like and slow to change. Researchers in this field are currently searching for additional methods for RF assessment. For instance, the RF Scale has been applied to transcripts of therapy sessions, capturing RF as a more fluctuating and state like phenomenon. So far this adaption has only been used on MBT sessions in a study of 15 patients with comorbid BPD and substance dependence.

To move forward in the understanding of RF and psychotherapy processes in more detail one should preferably apply different methods for RF assessment. A part of the present project is therefore to evaluate RF by three different methods based on 1) AAI , 2) in-session interactions, and 3) a specially developed interview focusing on episodes of temporary break down of mentalizing ability.

AIMS The overall aim of the project is to study psychotherapy processes in MBT for patients with BPD. It focuses on patients' mentalizing difficulties before, during and at the end of therapy. Mentalization is operationalized as RF and assessed using different methods. The projects aims to investigate the role of patients' RF for clinical outcome, change in RF during and across sessions, patient-therapist interactions promoting or hindering reflection, and other psychotherapy processes that might mediate treatment response. To render possible studies of more differentiated treatment responses the project includes a variety of outcomes, ranging from treatment attendance and dropout, clinical symptoms, personality related variables, global functioning, health service use, and rehabilitation support.

RESEARCH QUESTIONS

  1. To what degree does patients' level of RF change during MBT?
  2. Is there a relationship between RF and outcome of MBT?
  3. Does RF predict clinical outcome in MBT?
  4. Is outcome in MBT mediated by RF?
  5. Is change in RF associated with change in core BPD problems such as poor affect regulation, impulse control, and unstable relationships?
  6. What is the relationship between RF and therapy processes in MBT?
  7. Is RF related to patients' experience of therapeutic alliance in individual and group therapy?
  8. Is RF related to early drop-out and treatment completion?
  9. How does patients' RF interact with other patient characteristics in influencing therapeutic alliance and outcome?
  10. Is it possible to identify in-session processes that promote mentalizing?
  11. Does therapist adherence to MBT predict better patient in-session mentalizing or outcome?
  12. Which in-session processes, including therapist interventions, promote or impede patient mentalizing?
  13. What is the clinical utility of various methods of RF assessment?
  14. What are the relationships between interview based RF scored on AAI, BPD domain specific RF scored on a specifically developed "Mentalization breakdown interview", and observer rated RF based on video recordings of individual therapy sessions?
  15. What is the relationship between the various RF assessment methods and intensity and frequency of mentalization breakdowns?
  16. Do the different RF assessment methods perform differently regarding prediction and mediation of clinical outcome?

The project will be conducted at the Personality Outpatient Unit, Section of Personality Psychiatry, Oslo University Hospital, which is specialized in the treatment of patients with personality disorders. Currently the unit focuses primarily on BPD. A maximum of sixty consecutively admitted patients with BPD or BPD traits, age 18-40 years, and 6-10 therapists from the ordinary staff will be included as participants after informed consent.

Being tested
Mentalization based therapy
Medical subject headings
Borderline Personality Disorder

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Mentalization based therapyBehavioural

    Mentalization based therapy is a specialized treatment for patients with borderline personality disorder. The treatment program combines individual and group therapy, as well as psychoeducation

Study groups in NCT04157907
Study groupRoleWhat they receive
Patients with borderline personality disorderPatients with borderline personality disorder included in the MBT program
Receives: Behavioral: Mentalization based therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Work and Social Adjustments Scale, WSAS, change during treatment and 3 months follow-up

    Work and social adaption

    Measured: 6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  2. Global Assessment of Functioning, GAF, change during treatment and 3 months follow-up

    psychosocial functioning

    Measured: 6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  3. Patient Health Questionnaire, PHQ-9, change during treatment and 3 months follow-up

    depression

    Measured: 6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  4. Patient Health Questionnaire, GAD-7, change during treatment and 3 months follow-up

    anxiety

    Measured: 6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  5. Self-harm, self-report, change during treatment and 3 months follow-up

    Self-harm

    Measured: 6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  6. Suicide attempts, self-report, change during treatment and 3 months follow-up

    Suicide attempts

    Measured: 6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  7. Circumplex of Interpersonal Problems, CIP, change during treatment and 3 months follow-up

    interpersonal problems

    Measured: 6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  8. Severity Index of Personality Problems, SIPP-118, change during treatment and 3 months follow-up

    personality functioning

    Measured: 6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  9. Level of Personality Functioning Scale, LPFS BF, change during treatment and 3 months follow-up

    personality functioning

    Measured: 6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  10. Difficulties in Emotion Regulation Scale, DERS, change during treatment and 3 months follow-up

    emotional regulation

    Measured: 6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  11. Toronto Alexithymia Scale, TAS-20, change during treatment and 3 months follow-up

    alexithymia

    Measured: 6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  12. Reflective functioning based on AAI, change from baseline to 3 months follow-up

    reflective functioning

    Measured: 3 months follow-up

  13. Reflective functioning based on the mentalization breakdown interview, change during treatment and 3 months follow-up

    reflective functioning

    Measured: 6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  14. Reflective functioning based on therapy sessions, change during treatment

    reflective functioning

    Measured: 6, 12, 18, 24, 30 and 36 months

  15. Months in work or studies, self report, change during treatment and 3 months follow-up

    work functioning

    Measured: 6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  16. Experiences in Close relationships, ECR, change during treatment and 3 months follow-up

    attachment

    Measured: 6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  17. Suicide ideation, change during treatment and 3 months follow-up

    Suicide ideation

    Measured: 6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

Secondary outcomes (7)
  1. Substance use (from AUDIT and DUDIT), change during treatment and 3 months follow-up

    substance use

    Measured: 6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  2. EuroQoL, EQ-5D, change during treatment and 3 months follow-up

    quality of life

    Measured: 6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  3. Modified Overt Aggression Scale (selected items), change during treatment and 3 months follow

    aggression

    Measured: 6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  4. Working Alliance Inventory, WAI, change during treatment

    therapeutic alliance

    Measured: 6, 12, 18, 24, 30 and 36 months

  5. Group Questionnaire, GQ, change during treatment

    alliance in group therapy

    Measured: 6, 12, 18, 24, 30 and 36 months

  6. Client Satisfaction Scale, CSS, change during treatment and 3 months follow

    treatment satisfaction

    Measured: 6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

  7. Health service use / NAV contacts and support, change during treatment and 3 months follow

    Health services, social support and benefits

    Measured: 6, 12, 18, 24, 30 and 36 months, and 3 months follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Nov 2019
  2. Study start1 Nov 2019
  3. Primary completion28 Feb 2025 (estimated)
  4. Study completion28 Feb 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04157907
Sponsor's protocol ID
2018/0519
Status last verified
Nov 2019
First submitted
1 Nov 2019
Last updated
8 Nov 2019
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Ulvestad DA, Johansen MS, Kvarstein EH, Pedersen G, Wilberg T. Minding mentalizing - convergent validity of the Mentalization Breakdown Interview. Front Psychiatry. 2024 Jun 21;15:1380532. doi: 10.3389/fpsyt.2024.1380532. eCollection 2024.

    PubMed 38974920

Questions about this trial

What is this clinical trial studying?

An observational study of Borderline Personality Disorder, run by Oslo University Hospital at 1 site in Norway.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 8 Nov 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Theresa Wilberg, MD PhD (+47 22923433, uxthwi@ous-hf.no), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Work and Social Adjustments Scale, WSAS, change during treatment and 3 months follow-up (time frame: 6, 12, 18, 24, 30 and 36 months, and 3 months follow-up). The study lists 17 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04157907, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Nov 2019; AzTrials last refreshed its copy on 27 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in